[Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
Glazer
Anna
A
Läkemedelsverket, Uppsala. anna.glazer@hotmail.com
Hedenmalm
Karin
K
D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic / Q000592:standards*; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D035842:Research Subjects; D012449:Safety; D013548:Sweden
D000911:Antibodies, Monoclonal; D001688:Biological Products; D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations